Mrs Elaine K Burns, DPH | |
2962 Skipping Stone Dr, Apison, TN 37302-7543 | |
(423) 236-4660 | |
Not Available |
Full Name | Mrs Elaine K Burns |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 2962 Skipping Stone Dr, Apison, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164555298 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 5302024728 (Michigan) | Secondary |
183500000X | Pharmacist | 33415 (Tennessee) | Primary |
183500000X | Pharmacist | RPH025181 (Georgia) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Mrs Elaine K Burns, DPH 2962 Skipping Stone Dr, Apison, TN 37302-7543 Ph: (423) 236-4660 | Mrs Elaine K Burns, DPH 2962 Skipping Stone Dr, Apison, TN 37302-7543 Ph: (423) 236-4660 |
News Archive
There isn't a hard and fast rule for how long doctors should perform CPR, but new research from the University of Michigan Health System shows longer attempts might be beneficial for some patients.
Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development and commercialisation of its drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.
The Department of Industrial Relations' Division of Workers' Compensation (DIR/DWC) is on target to implement a workers' compensation drug formulary by July of next year as required by Assembly Bill 1124.
Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).
Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.
› Verified 5 days ago